GlassScriptPhysician profile
Nathan Jerome Cleaver
NPI 1871882225
$38,362.26
in general payments reported to CMS, 2019-2025
41 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $410 · 2021: $897 · 2022: $2,980 · 2023: $6,852 · 2024: $2,525 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Food and Beverage: $7,175 · Travel and Lodging: $1,089 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,366.25 |
| Food and Beverage | $7,174.92 |
| Travel and Lodging | $1,089.24 |
| Education | $277.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $11,750.56 | 2019-2025 | Ilumya, Odomzo, Winlevi |
| Sanofi US Services INC. | $10,036.25 | 2025 | |
| Ucb, INC. | $5,623.12 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $2,461.05 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Janssen Biotech, INC. | $2,004.26 | 2019-2025 | Tremfya |
| Genzyme Corporation | $966.63 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $527.67 | 2019-2025 | Dupixent, Libtayo |
| Merz North America, INC. | $513.47 | 2019-2025 | Xeomin |
| Leo Pharma INC. | $507.74 | 2022-2025 | Adbry |
| Galderma Laboratories, L.P. | $427.64 | 2019-2025 | Nemluvio |
| Boston Scientific Corporation | $354.31 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Dermavant Sciences, INC. | $319.64 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $316.79 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $288.00 | 2019-2025 | Jublia, Siliq, Duobrii |
| Pfizer INC. | $256.21 | 2019-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $255.46 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $213.48 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $211.55 | 2019-2024 | |
| Organon LLC | $146.56 | 2025 | Vtama |
| Journey Medical Corporation | $136.83 | 2022-2024 | |
| Organogenesis INC. | $120.32 | 2023-2025 | Cygnus Dual, Affinity, Puraply |
| Allergan, INC. | $119.22 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $116.50 | 2019-2020 | |
| Biofrontera INC. | $114.67 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $102.19 | 2022-2025 | Opzelura |
| Amgen INC. | $49.99 | 2022-2025 | Otezla |
| Avanos Medical | $49.93 | 2021 | |
| Vyne Pharmaceuticals INC. | $43.50 | 2020 | |
| Biotronik Nro, INC. | $38.85 | 2025 | |
| Pacira Therapeutics, INC. | $36.87 | 2019-2020 | |
| Genentech USA, INC. | $32.20 | 2021-2023 | Erivedge |
| Kerecis Limited | $31.43 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Medimetriks Pharmaceuticals, INC. | $25.15 | 2019 | |
| Botanix Sb INC | $24.44 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $24.18 | 2022 | |
| Abbott Laboratories | $23.07 | 2020 | |
| Verrica Pharmaceuticals INC. | $22.16 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $21.14 | 2023 | |
| Encore Dermatology INC. | $16.61 | 2019 | |
| Smith+Nephew, INC. | $16.52 | 2019 | |
| Spr Therapeutics, INC | $16.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Cleaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.